Divisions deepen over Pfizer's spurned bid for AstraZeneca
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The splits between big investors over AstraZeneca's decision to reject Pfizer's takeover attempt deepened yesterday.
The fund management titan Neil Woodford said he is "convinced that an independent AstraZeneca will achieve far better returns… than the combination of cash and Pfizer paper would have delivered."
Fidelity's chief investment officer Dominic Rossi, said: "I don't think that Pfizer was a suitable partner. It was motivated by tax and finance considerations.
"The Astra board has taken a very difficult decision. They understood in rejecting the offer they would be criticised by some shareholders. We will now have to wait two to three years to see whether they were right"
In contrast, Schroders was disappointed by the "quick rejection" and called on the UK group "to recommence their engagement with Pfizer".
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments